Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lyra Therapeutics (LYRA) EBITDA Margin (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed EBITDA Margin for 5 consecutive years, with 23936.0% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin fell 1785959.0% to 23936.0% in Q3 2025 year-over-year; TTM through Sep 2025 was 3529.66%, a 1016358.0% increase, with the full-year FY2023 number at 4021.63%, up 3325.0% from a year prior.
  • EBITDA Margin was 23936.0% for Q3 2025 at Lyra Therapeutics, down from 4063.93% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 830.11% in Q4 2024 to a low of 129318.18% in Q4 2022.
  • A 5-year average of 17264.93% and a median of 4221.8% in 2024 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: plummeted -12429346bps in 2022, then surged 11896476bps in 2023.
  • Lyra Therapeutics' EBITDA Margin stood at 5024.72% in 2021, then plummeted by -2474bps to 129318.18% in 2022, then skyrocketed by 92bps to 10353.42% in 2023, then soared by 108bps to 830.11% in 2024, then tumbled by -2983bps to 23936.0% in 2025.
  • Per Business Quant, the three most recent readings for LYRA's EBITDA Margin are 23936.0% (Q3 2025), 4063.93% (Q2 2025), and 4670.49% (Q1 2025).